CenterState CEO seeds Ichor macular degeneration program with Grants for Growth

LaFayette, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, has received a $25,000 grant from CenterState CEO through its Grants for Growth program. Announced in CenterState CEO’s February 2015 Newsletter, this funding will be used to develop an enzyme augmentation therapy to treat age-related macular degeneration, the leading cause of blindness and vision loss in Americans over the age of 50.

Ichor CEO Kelsey Moody said, “My team and I are very excited about this award and our new research program, but perhaps even more exciting is the budding culture of entrepreneurship here in Central New York. Seth Mulligan and Tony Kershaw are doing inspiring work to make CNY a desirable destination for entrepreneurs. Their efforts, coupled with initiatives like Governor Andrew Cuomo’s START-UP NY, will undoubtedly have a lasting, positive impact on the region.”

About Ichor Therapeutics, Inc.: Ichor Therapeutics, Inc. (www.ichortherapeutics.com) is a privately held pre-clinical biotechnology company in Syracuse, NY. Founded in 2013 by then SUNY Upstate Medical University student Kelsey Moody, the company has raised over $1 million to support its research programs. Ichor owns and operates the online store WeCellStuff.com.